Michael Renner, MD
Family Medicine · Bonaire, GANPI 1386602662
Payments from drug & device makers
Across 383 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$709
- Otsuka America Pharmaceutical, Inc.$546
- Lilly USA, LLC$508
- AbbVie$493
- Boehringer Ingelheim$486
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,76299%
- Education$491%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,706 |
| AstraZeneca | 25 | $709 |
| Otsuka America Pharmaceutical, Inc. | 31 | $546 |
| Lilly USA, LLC | 33 | $508 |
| AbbVie(2 entities) | 31 | $493 |
| Boehringer Ingelheim | 17 | $486 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $442 |
| Amgen | 21 | $384 |
| Bayer | 17 | $363 |
| Lundbeck LLC | 15 | $299 |
| Pfizer | 8 | $245 |
| Amarin Pharma, Inc. | 13 | $218 |
| Sanofi-aventis U.S. LLC | 13 | $208 |
| GSK | 5 | $204 |
| Merck | 4 | $141 |
| Novartis | 5 | $97 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $79 |
| Axonics, Inc. | 1 | $79 |
| Abbott | 4 | $77 |
| Arbor Pharmaceuticals, Inc. | 5 | $62 |
| Mannkind Corporation | 1 | $59 |
| Eisai Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Dexcom, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Medtronic | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Aytu Biopharma, Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,870 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 77 | $105,795 |
| RybelsusSemaglutide | 36 | $82,192 |
| EliquisApixaban | 40 | $55,899 |
| OzempicSemaglutide | 39 | $51,729 |
| FarxigaDapagliflozin Propanediol | 36 | $51,208 |
| JardianceEmpagliflozin | 45 | $45,729 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $34,557 |
| KerendiaFinerenone | 23 | $30,178 |
| EntrestoSacubitril/Valsartan | 19 | $27,752 |
| TrulicityDulaglutide | 23 | $24,326 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $23,537 |
| RexultiBrexpiprazole | 15 | $21,707 |
| Repatha SureclickEvolocumab | 18 | $18,487 |
| VascepaIcosapent Ethyl | 14 | $14,061 |
| JanuviaSitagliptin Phosphate | 13 | $12,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,706 | $133,92175 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $508 | $131,312115 claims |
| Boehringer IngelheimJardiance, Glyxambi | $486 | $58,13161 claims |
| PfizerEliquis | $245 | $55,89940 claims |
| AstraZenecaFarxiga | $709 | $51,20836 claims |
| BayerKerendia | $363 | $30,17823 claims |
| NovartisEntresto | $97 | $27,75219 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208 | $23,53720 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $546 | $21,70715 claims |
| MerckJanuvia | $141 | $12,65513 claims |
| AbbVieSynthroid | $493 | $1,15016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Bonaire
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.